Active Ingredient History

NOW
  • Now
Nemonoxacin is a non-fluorinated quinolone antibiotic undergoing clinical trials. It has the same mechanism of action as fluouroquinolones; it inhibits DNA gyrase, preventing DNA synthesis, gene duplication, and cell division. At the end of 2016, it had reached market in Taiwan, Russia, the Commonwealth Independent States, Turkey, mainland China, and Latin America under the brand name Taigexyn. Nemonoxacin has completed phase 2 trials in the US and has moved on to phase 3 trials. The U.S. Food and Drug Administration (FDA) has granted nemonoxacin qualified infectious disease product (QIDP) and fast track designations for community-acquired bacterial pneumonia (CAP) and acute bacterial skin and skin-structure infections (ABSSSI).   Wikipedia

  • SMILES: COc1c(ccc2C(=O)C(=CN(C3CC3)c12)C(=O)O)N4C[C@@H](C)C[C@H](N)C4
  • InChIKey: AVPQPGFLVZTJOR-RYUDHWBXSA-N
  • Mol. Mass: 371.44
  • ALogP: 2.22
  • ChEMBL Molecule:
More Chemistry
nemonoxacin | taigexyn | tg873870 | tg 873870 | tg-873870

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue